These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

519 related articles for article (PubMed ID: 9064324)

  • 1. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand.
    O'Connell J; O'Sullivan GC; Collins JK; Shanahan F
    J Exp Med; 1996 Sep; 184(3):1075-82. PubMed ID: 9064324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of cytokines in promoting immune escape of FasL-expressing human colon cancer cells.
    Xu T; Sun BC; Li Q; Hao XS
    World J Gastroenterol; 2005 Jul; 11(25):3915-9. PubMed ID: 15991293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fas ligand expression in primary colon adenocarcinomas: evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer.
    O'Connell J; Bennett MW; O'Sullivan GC; Roche D; Kelly J; Collins JK; Shanahan F
    J Pathol; 1998 Nov; 186(3):240-6. PubMed ID: 10211111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pancreatic cancer cells can evade immune surveillance via nonfunctional Fas (APO-1/CD95) receptors and aberrant expression of functional Fas ligand.
    von Bernstorff W; Spanjaard RA; Chan AK; Lockhart DC; Sadanaga N; Wood I; Peiper M; Goedegebuure PS; Eberlein TJ
    Surgery; 1999 Jan; 125(1):73-84. PubMed ID: 9889801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of counterattack of colorectal cancer cell by Fas/Fas ligand system.
    Zhu Q; Liu JY; Xu HW; Yang CM; Zhang AZ; Cui Y; Wang HB
    World J Gastroenterol; 2005 Oct; 11(39):6125-9. PubMed ID: 16273638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered mechanisms of apoptosis in colon cancer: Fas resistance and counterattack in the tumor-immune conflict.
    O'Connell J; Bennett MW; Nally K; Houston A; O'Sullivan GC; Shanahan F
    Ann N Y Acad Sci; 2000 Jun; 910():178-92; discussion 193-5. PubMed ID: 10911913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cutting edge: the tumor counterattack hypothesis revisited: colon cancer cells do not induce T cell apoptosis via the Fas (CD95, APO-1) pathway.
    Favre-Felix N; Fromentin A; Hammann A; Solary E; Martin F; Bonnotte B
    J Immunol; 2000 May; 164(10):5023-7. PubMed ID: 10799856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholangiocarcinomas express Fas ligand and disable the Fas receptor.
    Que FG; Phan VA; Phan VH; Celli A; Batts K; LaRusso NF; Gores GJ
    Hepatology; 1999 Dec; 30(6):1398-404. PubMed ID: 10573518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of Fas ligand in liver metastases of human colonic adenocarcinomas.
    Shiraki K; Tsuji N; Shioda T; Isselbacher KJ; Takahashi H
    Proc Natl Acad Sci U S A; 1997 Jun; 94(12):6420-5. PubMed ID: 9177233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fas ligand expression in colon cancer: a possible mechanism of tumor immune privilege.
    Zhang W; Ding EX; Wang Q; Zhu DQ; He J; Li YL; Wang YH
    World J Gastroenterol; 2005 Jun; 11(23):3632-5. PubMed ID: 15962391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fas receptor counterattack against tumor-infiltrating lymphocytes in vivo as a mechanism of immune escape in gastric carcinoma.
    Koyama S; Koike N; Adachi S
    J Cancer Res Clin Oncol; 2001 Jan; 127(1):20-6. PubMed ID: 11206267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model.
    Greil R; Egle A; Villunger A
    Leuk Lymphoma; 1998 Nov; 31(5-6):477-90. PubMed ID: 9922038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fas (Apo-1/CD95) and Fas ligand interaction between gastric cancer cells and immune cells.
    Lee TB; Min YD; Lim SC; Kim KJ; Jeon HJ; Choi SM; Choi CH
    J Gastroenterol Hepatol; 2002 Jan; 17(1):32-8. PubMed ID: 11895550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addressing the "Fas counterattack" controversy: blocking fas ligand expression suppresses tumor immune evasion of colon cancer in vivo.
    Ryan AE; Shanahan F; O'Connell J; Houston AM
    Cancer Res; 2005 Nov; 65(21):9817-23. PubMed ID: 16267003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human pancreatic cancer cells express non-functional Fas receptors and counterattack lymphocytes by expressing Fas ligand; a potential mechanism for immune escape.
    Elnemr A; Ohta T; Yachie A; Kayahara M; Kitagawa H; Ninomiya I; Fushida S; Fujimura T; Nishimura G; Shimizu K; Miwa K
    Int J Oncol; 2001 Jan; 18(1):33-9. PubMed ID: 11115536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance to Fas (APO-1/CD95)-mediated apoptosis and expression of Fas ligand in esophageal cancer: the Fas counterattack.
    O'Connell J; Bennett MW; O'Sullivan GC; Collins JK; Shanahan F
    Dis Esophagus; 1999; 12(2):83-9. PubMed ID: 10466039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survivin enhances Fas ligand expression via up-regulation of specificity protein 1-mediated gene transcription in colon cancer cells.
    Asanuma K; Tsuji N; Endoh T; Yagihashi A; Watanabe N
    J Immunol; 2004 Mar; 172(6):3922-9. PubMed ID: 15004200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance to Fas-mediated cell death in BeWo and NJG choriocarcinoma cell lines: implications in immune privilege.
    Rajashekhar G; Loganath A; Roy AC; Mongelli JM
    Gynecol Oncol; 2003 Oct; 91(1):89-100. PubMed ID: 14529667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of antitumor drugs on the expression of Fas system in SW480 colon cancer cells.
    Zhu Q; Liu JY; Yang CM; Xu HW; Zhang AZ; Cui Y; Wang HB; Qin CY; Li YQ
    Eur J Gastroenterol Hepatol; 2006 Oct; 18(10):1071-7. PubMed ID: 16957513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential sensitivity of CD4+ and CD8+ T lymphocytes to the killing efficacy of Fas (Apo-1/CD95) ligand+ tumor cells in B chronic lymphocytic leukemia.
    Tinhofer I; Marschitz I; Kos M; Henn T; Egle A; Villunger A; Greil R
    Blood; 1998 Jun; 91(11):4273-81. PubMed ID: 9596676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.